Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
What are your biggest takeaways from the MASH-TAG 2025 conference?
Related Questions
How do you approach a patient with discordant Fibroscan and serologic testing for fibrosis?
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
What testing do you utilize to decide a patient's candidacy for Resmetirom therapy?
How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?
What is your approach to a patient with an elevated alkaline phosphatase level, but negative PBC serologies and normal biliary imaging?
In what scenario do you continue surveillance of benign liver tumors, e.g., hepatocellular adenoma, in pregnant patients?
Is there benefit to aggressively treating hemochromatosis in a patient who has already progressed to cirrhosis at the time of diagnosis?
What kind of follow up or monitoring do you recommend for patients with at risk alpha-1-anti-trypsin phenotypes?
Do you always consider ADPCKD or ARPCKD in a patient who is incidentally found to have liver and renal cysts?
